Safety of the neprilysin/renin-angiotensin system inhibitor LCZ696

OBJECTIVES: The combined neprilysin/rennin-angiotensin system inhibitor sacubitril/valsartan (LCZ696) has shown its superiority over ACEI/ARB therapy. In view of the existing concern of its adverse effects, we aimed to provide evidence of the safety of the new drug. RESULTS: A total of 6 randomized...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Li, Bo, Zhao, Yunhe, Yin, Bo, Helian, Mengfei, Wang, Xinmei, Chen, Feng, Zhang, Hongxia, Sun, Hui, Meng, Bin, An, Fengshuang
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2017
Sujets:
Review
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5669972/
https://ncbi.nlm.nih.gov/pubmed/29137346
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.18312
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires